149 related articles for article (PubMed ID: 26014353)
1. Discovery and validation of vascular endothelial growth factor (VEGF) pathway polymorphisms in esophageal adenocarcinoma outcome.
Eng L; Azad AK; Qiu X; Kong QQ; Cheng D; Ying N; Tse A; Kuang Q; Dodbiba L; Renouf DJ; Marsh S; Savas S; Mackay HJ; Knox JJ; Darling GE; Wong RK; Xu W; Liu G; Faluyi OO
Carcinogenesis; 2015 Sep; 36(9):956-62. PubMed ID: 26014353
[TBL] [Abstract][Full Text] [Related]
2. VEGFA, FLT1, KDR and colorectal cancer: assessment of disease risk, tumor molecular phenotype, and survival.
Slattery ML; Lundgreen A; Wolff RK
Mol Carcinog; 2014 Feb; 53 Suppl 1():E140-50. PubMed ID: 23794399
[TBL] [Abstract][Full Text] [Related]
3. Validation of microRNA pathway polymorphisms in esophageal adenocarcinoma survival.
Faluyi OO; Eng L; Qiu X; Che J; Zhang Q; Cheng D; Ying N; Tse A; Kuang Q; Dodbiba L; Renouf DJ; Marsh S; Savas S; Mackay HJ; Knox JJ; Darling GE; Wong RK; Xu W; Azad AK; Liu G
Cancer Med; 2017 Feb; 6(2):361-373. PubMed ID: 28074552
[TBL] [Abstract][Full Text] [Related]
4. Genetic variations in angiogenesis pathway genes predict tumor recurrence in localized adenocarcinoma of the esophagus.
Lurje G; Leers JM; Pohl A; Oezcelik A; Zhang W; Ayazi S; Winder T; Ning Y; Yang D; Klipfel NE; Chandrasoma P; Hagen JA; DeMeester SR; DeMeester TR; Lenz HJ
Ann Surg; 2010 May; 251(5):857-64. PubMed ID: 20101173
[TBL] [Abstract][Full Text] [Related]
5. Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcome.
Korpanty GJ; Eng L; Qiu X; Faluyi OO; Renouf DJ; Cheng D; Patel D; Chen Z; Tse BC; Knox JJ; Dodbiba L; Teichman J; Azad AK; Wong R; Darling G; Reisman D; Cuffe S; Liu G; Xu W
Oncotarget; 2017 Apr; 8(17):28093-28100. PubMed ID: 28427211
[TBL] [Abstract][Full Text] [Related]
6. Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients.
Scartozzi M; Giampieri R; Loretelli C; Bittoni A; Mandolesi A; Faloppi L; Bianconi M; Del Prete M; Andrikou K; Bearzi I; Cascinu S
Pharmacogenomics; 2013 Dec; 14(16):1991-8. PubMed ID: 24090479
[TBL] [Abstract][Full Text] [Related]
7. Single-nucleotide polymorphisms in the vascular endothelial growth factor pathway and outcomes of patients treated with first-line cytotoxic chemotherapy combined with bevacizumab for advanced colorectal cancer.
Sohn BS; Park SJ; Kim JE; Kim KP; Hong YS; Suh C; Kim YS; Kim SY; Im SA; Kim SY; Kim JH; Ahn JB; Park YS; Kim TW
Oncology; 2014; 87(5):280-92. PubMed ID: 25139485
[TBL] [Abstract][Full Text] [Related]
8. An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure.
Ravegnini G; Nannini M; Zenesini C; Simeon V; Sammarini G; Urbini M; Gatto L; Saponara M; Biasco G; Pantaleo MA; Venturoli N; Hrelia P; Angelini S
Angiogenesis; 2017 Feb; 20(1):139-148. PubMed ID: 27896475
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer.
Kim JG; Chae YS; Sohn SK; Cho YY; Moon JH; Park JY; Jeon SW; Lee IT; Choi GS; Jun SH
Clin Cancer Res; 2008 Jan; 14(1):62-6. PubMed ID: 18172253
[TBL] [Abstract][Full Text] [Related]
10. Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.
Gampenrieder SP; Hufnagl C; Brechelmacher S; Huemer F; Hackl H; Rinnerthaler G; Romeder F; Monzo Fuentes C; Morre P; Hauser-Kronberger C; Mlineritsch B; Greil R
Pharmacogenomics J; 2017 Jul; 17(4):344-350. PubMed ID: 27139155
[TBL] [Abstract][Full Text] [Related]
11. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
Zhang L; Yuan X; Chen Y; Du XJ; Yu S; Yang M
Gene; 2013 Mar; 517(1):60-4. PubMed ID: 23313300
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration.
Hermann MM; van Asten F; Muether PS; Smailhodzic D; Lichtner P; Hoyng CB; Kirchhof B; Grefkes C; den Hollander AI; Fauser S
Ophthalmology; 2014 Apr; 121(4):905-10. PubMed ID: 24365177
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel.
Koutras AK; Kotoula V; Papadimitriou C; Dionysopoulos D; Zagouri F; Kalofonos HP; Kourea HP; Skarlos DV; Samantas E; Papadopoulou K; Kosmidis P; Pectasides D; Fountzilas G
Pharmacogenomics J; 2014 Jun; 14(3):248-55. PubMed ID: 24061601
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis.
Bradbury PA; Zhai R; Ma C; Xu W; Hopkins J; Kulke MJ; Asomaning K; Wang Z; Su L; Heist RS; Lynch TJ; Wain JC; Christiani D; Liu G
Clin Cancer Res; 2009 Jul; 15(14):4680-5. PubMed ID: 19584152
[TBL] [Abstract][Full Text] [Related]
15. Association of vascular endothelial growth factor (VEGF) and VEGF receptor gene polymorphisms with coronary artery lesions of Kawasaki disease.
Kariyazono H; Ohno T; Khajoee V; Ihara K; Kusuhara K; Kinukawa N; Mizuno Y; Hara T
Pediatr Res; 2004 Dec; 56(6):953-9. PubMed ID: 15470196
[TBL] [Abstract][Full Text] [Related]
16. Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma.
Renouf DJ; Zhai R; Sun B; Xu W; Cheung WY; Heist RS; Kulke MH; Cescon D; Asomaning K; Marshall AL; Li S; Christiani DC; Liu G
J Gastroenterol Hepatol; 2013 Sep; 28(9):1482-8. PubMed ID: 23735059
[TBL] [Abstract][Full Text] [Related]
17. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.
Lambrechts D; Claes B; Delmar P; Reumers J; Mazzone M; Yesilyurt BT; Devlieger R; Verslype C; Tejpar S; Wildiers H; de Haas S; Carmeliet P; Scherer SJ; Van Cutsem E
Lancet Oncol; 2012 Jul; 13(7):724-33. PubMed ID: 22608783
[TBL] [Abstract][Full Text] [Related]
18. Association of VEGF and KDR single nucleotide polymorphisms with colorectal cancer susceptibility in Koreans.
Jang MJ; Jeon YJ; Kim JW; Cho YK; Lee SK; Hwang SG; Oh D; Kim NK
Mol Carcinog; 2013 Nov; 52 Suppl 1():E60-9. PubMed ID: 23169005
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor receptor 2 gene polymorphisms as predictors for tumor recurrence and overall survival in non-small-cell lung cancer.
Uzunoglu FG; Kaufmann C; Wikman H; Güngör C; Bohn BA; Nentwich MF; Reeh M; Pantel K; Bockhorn M; Kutup A; Mann O; Izbicki JR; Vashist YK
Ann Surg Oncol; 2012 Jul; 19(7):2159-68. PubMed ID: 22395975
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 gene polymorphisms in patients with gastrointestinal stromal tumors.
Kang BW; Kim JG; Chae YS; Bae HI; Kwon O; Chung HY; Yu W; Song HS; Kang YN; Ryu SW; Lee KH; Bae YK; Choi JH; Kim SW; Ryoo HM; Cho CH; Chae HD; Park KW; Gu MJ; Bae BJ
Asia Pac J Clin Oncol; 2014 Jun; 10(2):e40-5. PubMed ID: 23551429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
